The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep Diseases

项目总结/摘要-总体 美国的医疗保健正在迅速发展到一个国家，在那里的效率和质量的医疗保健是 共同主导的驱动程序。几个新出现的趋势正在推动医疗保健的根本性变化： 1)越来越多的病人在负责任的护理组织与捆绑支付， 提供者; 2）强调质量指标，如减少心力衰竭再入院， 改善对高血压的控制;以及3）增加对患者的关注，作为医疗保健的驱动力。 决定和照顾的伙伴。现在迫切需要开发技术， 为护理人员和患者提供快速反馈，以便及时改变 患者自我护理、症状检测、诊断和治疗交付。特别是，有一个 迫切需要新的循证、用户友好、以患者为中心的床旁技术 （POCT）监测人们在日常生活中的健康/医疗状况， 并向护理点提供可操作的报告。推进点中心 心、肺、血液和睡眠疾病的护理技术（CAPCaT）将是一个分支， 一个非常成功的医疗产品孵化器，马萨诸塞州医疗器械开发 中心（M2 D2）在马萨诸塞州大学（洛厄尔和伍斯特校区）。的 M2 D2的创始目标是加速医疗设备的开发， 麻省大学洛厄尔分校（UML）在工程和商业方面的专业知识，以及临床 马萨诸塞大学医学院（UMMS）在伍斯特的专业知识。扩大视野， 由于M2 D2的成功，CAPCaT的目标是开发和优化新型POCT，以改善 心、肺、血液和睡眠（HLBS）疾病的诊断和管理。我们重点 由于与这些疾病相关的显著发病率，死亡率和成本， 疾病这些疾病加起来占美国死亡人数的41%， 4000亿美元的直接医疗保健费用加上受影响患者和护理人员的收入损失。 马萨诸塞大学在临床专业知识和技术开发方面有着良好的记录， HLBS疾病。我们的目标是：1）通过利益相关者的参与， 有前途的POCT，以解决未满足的医疗需求; 2）支持发展计划，包括 在护理点采用的途径;和3）培训和传播发展POCT， 不同的利益相关者。

PROJECT SUMMARY/ABSTRACT - OVERALL American healthcare is rapidly evolving to a state where efficiency and quality in health care are co-dominant drivers. Several emergent trends are driving fundamental changes in health care: 1) increasing numbers of patients in accountable care organizations with bundled payments to providers; 2) emphasis on quality metrics such as reducing readmissions for heart failure and improving control of hypertension; and 3) increasing focus on the patient as a driver of medical decisions and a partner in care. There is now an urgent need to develop technologies that provide rapid feedback to both caregivers and patients in order to effect timely changes in patient self-care, symptom detection, diagnosis and treatment delivery. In particular, there is a critical need for new evidence-based, user-friendly, patient-centric, point-of-care technologies (POCT) to monitor health/medical status in people as they go about their daily lives out of the clinic and to deliver actionable reports to the point of care. The Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Diseases will be an offshoot of a highly successful medical product incubator, the Massachusetts Medical Device Development Center (M2D2) at the University of Massachusetts (Lowell and Worcester campuses). The founding goal of M2D2 was to accelerate the development of medical devices, using the combined expertise of UMass Lowell (UML) in engineering and business, and the clinical expertise of UMass Medical School (UMMS) in Worcester. Expanding upon the vision and success of M2D2, the goal of CAPCaT is to develop and optimize novel POCT to improve the diagnosis and management of heart, lung, blood and sleep (HLBS) diseases. We have focused on these diseases because of the significant morbidity, mortality, and cost associated with these diseases. Combined, these diseases account for 41% of deaths in the US and lead to over $400B in direct health care expenses plus lost income to affected patients and caregivers. UMass has an established track record of clinical expertise and technology development in the HLBS diseases. Our objectives are to: 1) identify, through stakeholder engagement, the most promising POCTs to address unmet medical needs; 2) support developmental plans, including pathways to adoption at the point of care; and 3) train and disseminate developing POCT to the different stakeholders.